Softbank Group CORP. Has $69.34 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Softbank Group CORP. decreased its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 13.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 6,541,190 shares of the company's stock after selling 1,005,726 shares during the period. Neumora Therapeutics comprises 0.3% of Softbank Group CORP.'s portfolio, making the stock its 12th biggest position. Softbank Group CORP. owned about 4.05% of Neumora Therapeutics worth $69,337,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Capital International Investors raised its stake in shares of Neumora Therapeutics by 692.1% during the 4th quarter. Capital International Investors now owns 3,700,359 shares of the company's stock worth $39,224,000 after purchasing an additional 3,233,179 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its position in shares of Neumora Therapeutics by 273.9% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 521,013 shares of the company's stock valued at $5,523,000 after buying an additional 381,676 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Neumora Therapeutics by 4.5% during the 4th quarter. Vanguard Group Inc. now owns 4,572,308 shares of the company's stock worth $48,466,000 after acquiring an additional 195,142 shares during the period. Cutter Capital Management LP bought a new stake in Neumora Therapeutics in the 4th quarter valued at $1,590,000. Finally, Rock Springs Capital Management LP increased its holdings in shares of Neumora Therapeutics by 15.3% in the fourth quarter. Rock Springs Capital Management LP now owns 955,106 shares of the company's stock valued at $10,124,000 after purchasing an additional 127,005 shares during the last quarter. 47.65% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NMRA shares. Guggenheim cut shares of Neumora Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, March 7th. Royal Bank of Canada reissued a "sector perform" rating and issued a $4.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, March 4th. Needham & Company LLC reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday. HC Wainwright cut their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Finally, William Blair cut shares of Neumora Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, Neumora Therapeutics currently has a consensus rating of "Hold" and an average price target of $9.29.

Check Out Our Latest Analysis on Neumora Therapeutics

Neumora Therapeutics Trading Up 8.2%

Neumora Therapeutics stock opened at $0.67 on Friday. The stock has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $4.42. Neumora Therapeutics, Inc. has a 12 month low of $0.61 and a 12 month high of $17.19. The company has a market capitalization of $107.69 million, a PE ratio of -0.36 and a beta of 2.96.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.02). As a group, analysts predict that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

Read More

• Five stocks we like better than Neumora Therapeutics
• 2 Fintech Stocks to Buy Now and 1 to Avoid
• CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
• What is a Bond Market Holiday? How to Invest and Trade
• Analysts and Institutions Continue to Bet Big on Alphabet
• Trading Stocks: RSI and Why it's Useful
• Walmart Stock Alert: Big Price Move Expected Soon

Want to see what other hedge funds are holding NMRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Neumora Therapeutics Right Now?

Before you consider Neumora Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.

While Neumora Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here